Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Flexeril

This article was originally published in The Tan Sheet

Executive Summary

OTC rights retained by Merck under transaction divesting Rx sales and marketing rights for the muscle relaxant and exclusive trademark rights in the U.S. and Canada to Alza. Merck receives up-front and milestone payments under deal. Alza currently is developing a once-a-day formulation of cyclobenzaprine. Merck says it is continuing discussions with FDA about switching Flexeril OTC. In July 1999, NDAC expressed concerns about patients' ability to accurately detect when to use OTC Flexeril 5 mg but did not take a formal vote on a switch (1"The Tan Sheet" July 26, 1999, p. 3)
Advertisement

Related Content

Flexeril Indications Self-Diagnosis Seen As Significant Hurdle By Committee
Flexeril Indications Self-Diagnosis Seen As Significant Hurdle By Committee

Topics

Advertisement
UsernamePublicRestriction

Register

PS092196

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel